Ticker

ST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has completed its previously announced acquisition of Robocath, an innovator of robotic technologies for interventional cardiology and neurointerventions.

Stereotaxis NYSEAMERICAN: STXS said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products and the launch of its GenesisX robotic system.

Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.

Proprietary robotically-navigated MAGiC catheter received U. S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe Synchrony digital operating room system received U. S. FDA clearance in April and initial orders and shipments are ongoing Definitive agreement to acquire Robocath creates a leading robotic platform, combining complementary technologies to…